ArticleBMC complementary medicine and therapies2022
Anticancer potential of Phoenix dactylifera L. seed extract in human cancer cells and pro-apoptotic effects mediated through caspase-3 dependent pathway in human breast cancer MDA-MB-231 cells: an in vitro and in silico investigation.
Article in BMC complementary medicine and therapies, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 70 citations in OpenAlex.
- Pooled it
- Harnessing the power of date fruit: nutritional, bioactive, and functional roles in sustainable nutrition.Biodegradation · 2026Review
- Valorization of Date Palm (Molecules (Basel, Switzerland) · 2026Review
- Nutraceuticals ofDrug design, development and therapy · 2026Review
- Phytochemicals in overcoming venetoclax resistance in acute myeloid leukemia: mechanistic insights and therapeutic potential.Annals of hematology · 2025Review
- Nature-Inspired Strategies in Cancer Management: The Potential of Plant Extracts in Modulating Tumour Biology.International journal of molecular sciences · 2025Review
- Bioactive Properties of the Microwave-Assisted Olive Leaf Extract and Its Incorporation into a Whey Protein Isolate Coating of Semi-Hard Cheese.Foods (Basel, Switzerland) · 2025Article
- Network Pharmacology andCurrent pharmaceutical design · 2025Article
- Functional foods and exercise in breast cancer: epigenetic modulation, chemotherapy tolerance, and fatigue management.Frontiers in nutrition · 2025Review
- Unveiling the Neuroprotective Potential of Date Palm (Pharmaceuticals (Basel, Switzerland) · 2024Review
- Cytotoxic Effect of Phoenix dactylifera (Iraqi Date) Leaves and Fruits Extracts against Breast Cancers Cell Lines.Asian Pacific journal of cancer prevention : APJCP · 2024Article
- Antimicrobial peptide moricin induces ROS mediated caspase-dependent apoptosis in human triple-negative breast cancer via suppression of notch pathway.Cancer cell international · 2023Article
- Date Palm Fruit (Nutrients · 2023Review
- Targeting KK-LC-1 inhibits malignant biological behaviors of triple-negative breast cancer.Journal of translational medicine · 2023Article
- Article
- Arecaceae Seeds Constitute a Healthy Source of Fatty Acids and Phenolic Compounds.Plants (Basel, Switzerland) · 2023Article
- Chemical, biological andFrontiers in chemistry · 2023Article
- Bioactive profiling and evaluation of anti-proliferative and anti-cancerous properties of Shivagutika, an Indian polyherbal formulation synchronizingFrontiers in chemistry · 2023Article
- Biochemical Composition and Biological Activities of Date Palm (Biomolecules · 2022Review
- Polyphenol-Rich Date Palm Fruit Seed (Nutrients · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPhoenix dactylifera L. has a diverse set of pharmacological properties due to its distinct phytochemical profile. The purpose of this study was to investigate the anticancer potential of Phoenix dactylifera seed extract (PDSE) in human breast cancer MDA-MB-231 and MCF-7 cells, as well as liver cancer HepG2 cells, and to investigate the anticancer efficacy in triple-negative MDA-MB-231 cells, followed by in silico validation of the molecular interaction between active components of PDSE and caspase-3, an apoptosis executioner protein .
methodsIn this study, human cancer cell lines were cultured and subsequently treated with 10 to 100 μg/mL of PDSE. MTT test was performed to determine the cell viability, MMP was measured using fluorescent probe JC-1, nuclear condensation was determined by Hoechst 33258 dye, Annexin V-FITC & PI staining and cell cycle analysis were evaluated through flow cytometer, and apoptotic markers were detected using western blotting. The bioactive agents in PDSE were identified using high-performance liquid chromatography (HPLC) analysis. The binding affinity was validated using molecular docking tools AutoDock Vina and iGEMDOCK v2.1.
resultsCell viability data indicated that PDSE inhibited cell proliferation in both breast cancer cells and liver cancer cells. MDA-MB-231 cells showed maximum growth inhibition with an IC
conclusionPDS could serve as a potential medicinal source for apoptotic cell death in human breast cancer cells and, thus, could be used as a promising and crucial candidate in anticancer drug development. This study warrants further in vivo research, followed by clinical investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.